# Pizarra — PT-pseudo_0615b2bd8504 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_0615b2bd8504
Task: 1

Encounter: Urology - outpatient on 26 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 160.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 2.635 ng/mL²
  - PSA velocity: 35.73 ng/mL/yr
  - Prior PSA: 115.9 ng/mL
  - Prostate volume: 60.71 mL
  - Months since last PSA: 1
  - DRE findings: Abnormal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.95889634 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 160 ng/mL. PI-RADS 5. PSAD 2.63. Prostate volume 61 mL. DRE abnormal. csPCa 0.96.

Vitals: weight 93 kg, height 191 cm, BMI 25.5, BP 140/81 mmHg, HR 48 bpm. Smoking: Current smoker (20 pack-yr).

Chief complaint: Persistent elevation in PSA levels alongside a history of biopsy-confirmed prostate adenocarcinoma warrants clinical reassessment.

History: Now aged 63-year-old, the individual works as a retired bank clerk and Lives in ground-floor apartment with partner. Following an initial PSA measurement of 55.0 ng/mL in late 2022, a prior biopsy bucket "Positive" was documented. He maintains a Married status and engages in light resistance training twice weekly, complemented by a moderate alcohol intake of 14 units per week. Current smoker (20 pack-yr) status is noted, though he explicitly denies haematuria, pelvic discomfort, or lower urinary tract symptoms exceeding a baseline IPSS of 10. Past medical reviews include a routine hearing evaluation, an orthopaedic check for stable knee osteoarthritis, and a memory clinic assessment revealing intact cognition. He has never utilized 5-alpha-reductase inhibitors. General health remains excellent with an ECOG performance status of 0. Comorbidities: none. Active medication: None.

Physical examination: DRE — texture: firm and irregular nodule palpable in the left posterior peripheral zone; mobility: fixed; asymmetry: pronounced enlargement with right lobe induration but no distinct discrete masses; overall classification: cT3a. Abnormal DRE confirmed. Vital signs record a blood pressure of 140/81 mmHg and a resting heart rate of 48 bpm. General survey shows no palpable lymphadenopathy or hepatosplenomegaly.

Patient info: retired bank clerk; Married; Lives in ground-floor apartment with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 14 units / week; exercise Light weight-training at home, 2x/week; IPSS score: 10/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Orthopaedic outpatient — knee follow-up; Memory clinic — baseline screening.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.33 +/- 0.13   (95% CI 0.07-0.60)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.13  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.92 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'supports': p +/- dp does not cross 0.5 but p +/- 1.96*dp does. A direction, not a conclusion; a weighted vote. Measured accuracy in this tier on the labelled cohort: 0.8 over 20 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size and zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value of 160.0 ng/mL?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy or further action, as the initial panel is inconclusive. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the high-risk features like the PI-RADS 5 score, the very high PSA (160.0 ng/mL), and the significant PSA velocity (35.73 ng/mL/yr). It did not reason about the clinical context of a prior positive biopsy in relation to the current high-risk imaging.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.33 +/- 0.13. This suggestion could be wrong because the model failed to account for the high-risk profile. The high aleatoric uncertainty (H=0.92) indicates the model is highly uncertain about this specific patient, suggesting the disagreement lies in the data itself, likely due to the combination of a PI-RADS 5 and a prior positive biopsy.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology report - Does the current mpMRI lesion size and zone compare against an earlier study?
2. psa_trend - What is the serial PSA trend beyond the headline value of 160.0 ng/mL?
3. previous_notes - What was the prior grade, surveillance pathway, and management agreement?
4. previous GP / urology consultation notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
Guidelines suggest that the decision depends on whether the prior grade is documented, if the lesion changed against a previous MRI, and whether surveillance re-biopsy is due.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 5 lesion in the left peripheral zone with suspected extracapsular extension. Lesion size is approximately 35 mm. No comparison with a previous MRI was explicitly detailed in the report prose.
get_psa_trend
PSA trend: PSA increased from 14.8 ng/mL (Aug 2022) to 160.0 ng/mL (Jan 2025). The trend shows a significant rise, with a value of 160.0 ng/mL in Jan 2025.
get_previous_notes
Previous notes: Prior biopsy confirmed Gleason 3+4 pathology on 31 May 2024. The patient was on an expedited outpatient urology visit following a rise to 115.9 ng/mL in Feb 2023. Management agreement was for advanced imaging and procedural planning.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and no new laboratory questions arose from the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion with suspected extracapsular extension.
- PSA trend: Significant rise from 14.8 ng/mL to 160.0 ng/mL over 2 years.
- Previous notes: Prior biopsy confirmed Gleason 3+4 pathology, and the patient was scheduled for advanced imaging/procedural planning.

AGAINST sampling this patient now:
- Previous notes: No explicit documentation of a current active surveillance protocol or a specific protocol biopsy due date.

WHERE THIS LEANS
The evidence strongly supports the need for further investigation given the high-risk MRI findings and the significant PSA velocity, despite the prior positive biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence strongly supports the need for further investigation (LEAN: biopsy) due to the PI-RADS 5 MRI and significant PSA rise, despite the prior positive biopsy. The record is sufficient to proceed to the final decision.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the high-risk features like the PI-RADS 5 score, the very high PSA (160.0 ng/mL), and the significant PSA velocity (35.73 ng/mL/yr). It did not reason about the clinical context of a prior positive biopsy in relation to the current high-risk imaging.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.33 +/- 0.13. This suggestion could be wrong because the model failed to account for the high-risk profile. The high aleatoric uncertainty (H=0.92) indicates the model is highly uncertain about this specific patient, suggesting the disagreement lies in the data itself, likely due to the combination of a PI-RADS 5 and a prior positive biopsy.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology report - Does the current mpMRI lesion size and zone compare against an earlier study?
2. psa_trend - What is the serial PSA trend beyond the headline value of 160.0 ng/mL?
3. previous_notes - What was the prior grade, surveillance pathway, and management agreement?
4. previous GP / urology consultation notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
Guidelines suggest the decision depends on whether the prior grade is documented, if the lesion changed against a previous MRI, and whether surveillance re-biopsy is due.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 5 lesion in the left peripheral zone with suspected extracapsular extension. Lesion size is approximately 35 mm. No comparison with a previous MRI was explicitly detailed in the report prose.
get_psa_trend
PSA trend: PSA increased from 14.8 ng/mL (Aug 2022) to 160.0 ng/mL (Jan 2025). The trend shows a significant rise, with a value of 160.0 ng/mL in Jan 2025.
get_previous_notes
Previous notes: Prior biopsy confirmed Gleason 3+4 pathology on 31 May 2024. The patient was on an expedited outpatient urology visit following a rise to 115.9 ng/mL in Feb 2023. Management agreement was for advanced imaging and procedural planning.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and no new laboratory questions arose from the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion with suspected extracapsular extension.
- PSA trend: Significant rise from 14.8 ng/mL to 160.0 ng/mL over 2 years.
- Previous notes: Prior biopsy confirmed Gleason 3+4 pathology, and the patient was scheduled for advanced imaging/procedural planning.

AGAINST sampling this patient now:
- Previous notes: No explicit documentation of a current active surveillance protocol or a specific protocol biopsy due date.

WHERE THIS LEANS
The evidence strongly supports the need for further investigation given the high-risk MRI findings and the significant PSA velocity, despite the prior positive biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The agenda was fulfilled, and the retrieved evidence strongly leans towards biopsy. The conference closes, noting the unresolved disagreement between the statistical prior and the evidence.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The statistical prior suggested no biopsy, but the retrieved evidence strongly leans toward biopsy due to the PI-RADS 5 finding and the significant PSA rise from 14.8 ng/mL to 160.0 ng/mL. The guideline criterion abstained because the panel was inconclusive, leaving the retrieved documents as the deciding factor. The evidence supporting biopsy was overturned by the statistical prior's suggestion because the retrieved MRI report explicitly noted a PI-RADS 5 lesion with suspected extracapsular extension.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
